Abstract
We report the emergence of OXA-48 carbapenemase-producing Escherichia coli in Austria causing ventilator-associated pneumonia in a traveler returning from Egypt. Depending on resistance testing, quinolones may remain a therapeutic option for infections caused by these multiple resistant pathogens, as this class of drugs has a favorable safety and tolerability profile when compared to the alternatives. In this patient, however, the clinical course was dramatically complicated by the development of ciprofloxacin-associated rhabdomyolysis.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / adverse effects
-
Anti-Bacterial Agents / therapeutic use
-
Ciprofloxacin / adverse effects*
-
Ciprofloxacin / therapeutic use
-
Escherichia coli / isolation & purification*
-
Escherichia coli Infections / etiology*
-
Escherichia coli Infections / microbiology
-
Escherichia coli Proteins
-
Humans
-
Male
-
Middle Aged
-
Pneumonia, Ventilator-Associated / microbiology*
-
Rhabdomyolysis / chemically induced*
-
Rhabdomyolysis / microbiology*
-
beta-Lactamases
Substances
-
Anti-Bacterial Agents
-
Escherichia coli Proteins
-
Ciprofloxacin
-
beta-Lactamases